Last updated on July 2018

Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Brief description of study

This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (SALCL).

Clinical Study Identifier: NCT01909934

Find a site near you

Start Over

ZNA Stuivenberg

Antwerpen, Belgium
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

The Christie

Manchester, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.